DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
RANCHO CORDOVA, Calif., March 06, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that Joe Balagot, senior vice president of corporate development, will present an overview of the company, with a focus on its automated, closed systems for manufacturing CAR-T and other cell therapies, at the BIO-Europe Spring 12th Annual International Partnering Conference, which is being held March 12-14 at the Amsterdam RAI Convention Center in Amsterdam, The Netherlands.
Mr. Balagot’s presentation is scheduled to take place on Tuesday, March 13 at 3:30pm CET in Room E106.
With a focus on European innovation and global collaboration, BIO-Europe Spring 2018 is the premier springtime partnering conference bringing together executives from biotech, pharma and finance in the most innovative biopharma clusters in Europe. For more information about the conference, go to: https://ebdgroup.knect365.com/bioeurope-spring/
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
